title: Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.
abstract: OBJECTIVE
  To determine whether the metabolic features of breast tumours differ among molecular subtypes.
  
  
  METHODS
  This prospective study included 168 women diagnosed with locally advanced breast cancer. PET/CT was requested in the initial staging before neoadjuvant treatment (multicentre study, FISCAM grant). All patients underwent an ¹⁸F-FDG PET/CT scan with a dual time-point acquisition. Both examinations (PET-1 and PET-2) were evaluated qualitatively and semiquantitatively with calculation of SUVmax (SUV-1 and SUV-2, respectively), and the percentage variation in the SUVs and retention indexes (RI) between PET-1 and PET-2 in the breast tumour were calculated. Biological prognostic parameters, including the steroid receptor status, HER-2 expression, proliferation rate (Ki-67) and grading, were determined from primary tumour tissue. Tumour subtypes were classified following the recommendations of the 12th International Breast Conference, by immunohistochemical surrogates as luminal A, luminal B-HER2(-), luminal B-HER2(+), HER2(+) or basal. Metabolic semiquantitative parameters and molecular subtypes were correlated.
  
  
  RESULTS
  Of the 168 tumours, 151 were classified: 16 were luminal A, 53 were luminal B-HER2(-), 29 were luminal B-HER2(+), 18 were HER2(+) and 35 were basal. There were significant differences between SUV-1 and SUV-2 and the different subtypes, with higher SUVs in HER2(+) and basal tumours. No significant differences were found with respect to RI.
  
  
  CONCLUSIONS
  Semiquantitative metabolic parameters showed statistically significant differences among the molecular subtypes of the tumours evaluated. Therefore, there seems to be a relationship between molecular and glycolytic phenotypes.
authors: Nuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain. angarvice@yahoo.es
authors: Ana María
authors: AM
authors: García Vicente
authors: Ángel
authors: Á
authors: Soriano Castrejón
authors: Alberto
authors: A
authors: León Martín
authors: Ignacio
authors: I
authors: Chacón López-Muñiz
authors: Vicente
authors: V
authors: Muñoz Madero
authors: María del Mar
authors: Mdel M
authors: Muñoz Sánchez
authors: Azahara
authors: A
authors: Palomar Muñoz
authors: Ruth
authors: R
authors: Espinosa Aunión
authors: Ana
authors: A
authors: González Ageitos
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000378:metabolism; D002277:Carcinoma / Q000145:classification / Q000175:diagnosis* / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism*; D008327:Mammography; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D016217:Ultrasonography, Mammary
chemical_list: D019788:Fluorodeoxyglucose F18; D019394:Ki-67 Antigen; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references: Breast Cancer Res Treat. 2009 May;115(2):325-33
references: 18563552
references: Jpn J Clin Oncol. 2008 Apr;38(4):250-8
references: 18407934
references: Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):308-14
references: 23084013
references: PLoS Med. 2010 May 25;7(5):e1000279
references: 20520800
references: Clin Nucl Med. 2012 May;37(5):460-6
references: 22475895
references: Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35
references: 21057787
references: Rev Esp Med Nucl. 2009 Mar-Apr;28(2):85-9
references: 19406058
references: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references: 19204204
references: J Nucl Med. 2006 Sep;47(9):1440-6
references: 16954551
references: Breast Cancer. 2007;14(3):260-8
references: 17690502
references: Br J Surg. 2009 Feb;96(2):166-70
references: 19160365
references: J Nucl Med. 1998 Jan;39(1):4-8
references: 9443729
references: PLoS One. 2011;6(5):e20297
references: 21655258
references: PLoS One. 2012;7(4):e35881
references: 22563412
references: Mol Oncol. 2011 Feb;5(1):5-23
references: 21147047
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: Am Surg. 2007 Nov;73(11):1151-7
references: 18092653
references: Ann Surg Oncol. 2009 Oct;16(10):2705-10
references: 19593632
references: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references: 12829800
references: J Nucl Med. 2005 Nov;46(11):1819-24
references: 16269595
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Breast Cancer Res Treat. 2011 May;127(1):133-42
references: 21221771
references: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references: 19436038
references: Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1317-23
references: 12271413
references: Clin Radiol. 2008 Nov;63(11):1213-27
references: 18929039
references: Ann Oncol. 2011 Aug;22(8):1736-47
references: 21709140
references: Int J Clin Oncol. 2010 Dec;15(6):588-93
references: 20809217
references: J Nucl Med. 2010 Apr;51(4):543-50
references: 20237034
references: J Nucl Med. 2007 Aug;48(8):1266-72
references: 17631558
references: J Nucl Med. 2001 Jan;42(1):9-16
references: 11197987
references: Clin Breast Cancer. 2008 Jun;8(3):249-56
references: 18650155
references: Curr Mol Med. 2012 Jan;12(1):96-110
references: 22082486
references: Cancer. 2008 Mar 1;112(5):995-1000
references: 18098228
references: Mol Cell Biol. 2001 Sep;21(17):5899-912
references: 11486029
references: Breast. 2009 Oct;18 Suppl 3:S32-6
references: 19914539
references: J Clin Oncol. 2005 Oct 10;23(29):7350-60
references: 16145060
references: Oncology. 2011;80(5-6):341-9
references: 21791944
references: Eur J Radiol. 2009 Jun;70(3):530-8
references: 18395387